You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Surufatinib

Showing 1 - 25 of 72
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer Trial (HAIC, Surufatinib, Tislelizumab)

Not yet recruiting
  • Carcinoma
  • +7 more
  • (no location specified)
Nov 12, 2023

Bile Duct Adenocarcinoma Trial in Hangzhou (surufatinib plus cadonilimab)

Recruiting
  • Bile Duct Adenocarcinoma
  • surufatinib plus cadonilimab
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 15, 2023

Ampullary Carcinoma Trial (Surufatinib+Toripalimab+AG)

Not yet recruiting
  • Ampullary Carcinoma
  • (no location specified)
Sep 29, 2023

Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma

Not yet recruiting
  • Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
  • Surufatinib + envafolimab
  • (no location specified)
Feb 1, 2023

Osteosarcoma Trial (Surufatinib plus chemo, Chemotherapy)

Not yet recruiting
  • Osteosarcoma
  • (no location specified)
Jun 29, 2023

Surufatinib in G3 Neuroendocrine Tumors

Not yet recruiting
  • Neuroendocrine Tumor Grade 3
  • Surufatinib
  • (no location specified)
Aug 2, 2023

Differentiated Thyroid Cancer Trial in Shanghai (surufatinib)

Recruiting
  • Differentiated Thyroid Cancer
  • surufatinib
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 9, 2023

Soft Tissue Sarcoma Adult Trial (Surufatinib)

Not yet recruiting
  • Soft Tissue Sarcoma Adult
  • Surufatinib
  • (no location specified)
Oct 29, 2023

Advanced Solid Tumors With Neuroendocrine Differentiation Trial (surufatinib?serplulimab)

Not yet recruiting
  • Advanced Solid Tumors With Neuroendocrine Differentiation
  • (no location specified)
Nov 27, 2023

Surufatinib Plus Sintilimab Combined With Chemotherapy in

Recruiting
  • Gastric Neuroendocrine Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 22, 2023

Neuroendocrine Tumors Trial in Beijing (Surufatinib Combined With Temozolomide and S-1)

Not yet recruiting
  • Neuroendocrine Tumors
  • Surufatinib Combined With Temozolomide and S-1
  • Beijing, Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 8, 2023

Small Cell Lung Cancer Trial in Fuzhou (Surufatinib,Serplulimab,Etoposide,Carboplatin)

Not yet recruiting
  • Small Cell Lung Cancer
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital
May 20, 2023

Pancreatic Cancer Trial in Tianjin (surufatinib + gemcitabine + nab-paclitaxel)

Recruiting
  • Pancreatic Cancer
  • surufatinib + gemcitabine + nab-paclitaxel
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jun 15, 2023

Renal Impairment Trial in Tustin, Orlando (Surufatinib)

Completed
  • Renal Impairment
  • Surufatinib
  • Tustin, California
  • +1 more
Nov 2, 2022

Advanced NSCLC Trial in Guangzhou (Surufatinib, Surufatinib Plus Vinorelbine)

Recruiting
  • Advanced Non-Small Cell Lung Cancer
  • Surufatinib
  • Surufatinib Plus Vinorelbine
  • Guangzhou, Guangdong, China
    Affiliated Cancer Hospital and Institute of Guangzhou Medical Un
Aug 18, 2022

Colorectal Tumors Trial in Wuhan (Surufatinib)

Recruiting
  • Colorectal Neoplasms
  • Chohort 1: Surufatinib
  • +2 more
  • Wuhan, Hubei, China
    Hubei Cancer Hospital
Nov 5, 2022

Neuroendocrine Carcinoma Trial in Wuhan (Surufatinib and Serplulimab)

Not yet recruiting
  • Neuroendocrine Carcinoma
  • Surufatinib and Serplulimab
  • Wuhan, Hubei, China
    Cancer Center, Union Hospital, Tongji Medical College, Huazhong
Feb 18, 2023

Ovarian Cancer Trial in Hefei (Pamiparib, Surufatinib)

Recruiting
  • Ovarian Cancer
  • Hefei, Anhui, China
    Anhui Cancer Hospital
Dec 6, 2022

Small Cell Lung Cancer, Angiogenesis, Chemo Effect Trial (Surufatinib, Irinotecan)

Not yet recruiting
  • Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Nov 27, 2022

Hepatic Impairment Trial in Tustin, Orlando (Surufatinib)

Completed
  • Hepatic Impairment
  • Surufatinib
  • Tustin, California
  • +1 more
Aug 29, 2022

Metastatic Triple-negative Breast Cancer Trial in Wuhan (Surufatinib, Tislelizumab)

Not yet recruiting
  • Metastatic Triple-negative Breast Cancer
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Feb 27, 2023

Unresectable Locally Advanced or Metastatic Pancreatic Cancer Trial in Shanghai (surufatinib, KN046, gemcitabine)

Not yet recruiting
  • Unresectable Locally Advanced or Metastatic Pancreatic Cancer
  • surufatinib
  • +3 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Apr 16, 2023

High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)

Recruiting
  • High-Risk Localized Soft Tissue Sarcoma
  • Surufatinib
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 20, 2023

Extensive-stage Small-cell Lung Cancer Trial (Surufatinib Durvalizumab EP/EC)

Not yet recruiting
  • Extensive-stage Small-cell Lung Cancer
  • Surufatinib Durvalizumab EP/EC
  • (no location specified)
Dec 20, 2022

NSCLC Trial in Guangzhou (Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Guangzhou, Guang Dong, China
    Sun Yat-sen University Cancer Center
Nov 3, 2022